BridgeBio Pharma (BBIO) Gross Margin (2020 - 2026)
BridgeBio Pharma (BBIO) posted Gross Margin of 94.89% for Q1 2026, little changed sequentially from 94.74% in Q4 2025, and down 285.0% YoY from 51.29% in Q1 2025.
Powered by 
Analysis
BridgeBio Pharma (BBIO) Gross Margin (2020 - 2026) Analysis & Trends
BridgeBio Pharma has reported Gross Margin for 7 years, with the latest figure at 94.89% in Q1 2026.
- Quarterly Gross Margin fell 285.0% year-over-year to 94.89% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 95.13% (down 23.0% YoY) and the FY2025 annual result came in at 95.82%, down 243.0% from the prior year.
- Gross Margin was little changed at 94.89% in Q1 2026 per BBIO's latest filing, from 94.74% in the prior quarter.
- Over five years, Gross Margin peaked at 99.72% in Q1 2024 and troughed at 118.64% in Q3 2022.
- A 5-year average of 66.98% and a median of 78.11% in 2024 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2022 and 2023: Gross Margin plunged 15661 bps in 2022, then surged 20402 bps in 2023.
- Over 5 years, Gross Margin stood at 65.4% in 2022, then grew by 1 bps to 65.73% in 2023, then slipped by 2 bps to 64.57% in 2024, then soared by 47 bps to 94.74% in 2025, then gained by 0 bps to 94.89% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 94.89%, 94.74%, and 94.56% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | BridgeBio Pharma | 14.65 Bn | 13.93 Bn | 228.63 Mn | 93.83% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 93.83% |
| Mar 31, 2026 | 94.89% |
| Dec 31, 2025 | 94.74% |
| Sep 30, 2025 | 94.56% |
| Jun 30, 2025 | 96.70% |
| Mar 31, 2025 | 97.74% |
| Dec 31, 2024 | 64.57% |
| Sep 30, 2024 | 78.11% |
| Jun 30, 2024 | 72.42% |
| Mar 31, 2024 | 99.72% |
| Dec 31, 2023 | 65.73% |
| Sep 30, 2023 | 85.38% |
| Jun 30, 2023 | 63.50% |
| Mar 31, 2023 | 64.35% |
| Dec 31, 2022 | 65.40% |
| Sep 30, 2022 | -118.64% |
| Jun 30, 2022 | 99.05% |
| Mar 31, 2022 | 20.43% |
| Dec 31, 2021 | 84.49% |
| Sep 30, 2021 | 37.97% |